Metabolic reprogramming is one of the key hallmarks in acquiring aggressive phenotype and chemoresistance in many cancers including T-cell acute lymphoblastic leukemia (T-ALL). To combat chemoresistance, we treated patient-derived xenografts with two metabolic drugs that target two different pathways for T-ALL: IACS-010759, a Complex I inhibitor for OXPHOS pathway and AZD3965, a monocarboxylate transporter-1 (MCT1) inhibitor. Hyperpolarized metabolic imaging in vivo and NMR metabolomics ex vivo was utilized to observe the difference in metabolism with single treatment and in combination. Our results demonstrate that metabolic intervention utilizing OXPHOS blockade can be potentiated by targeting the MCT1 transporter.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords